Earth Science Tech's B2B-B2C Healthcare Platform Drives Revenue Growth and Financial Turnaround

Earth Science Tech Inc. (OTC: ETST) is making waves in the healthcare sector with its vertically integrated platform that combines compounding pharmacy operations, telemedicine, clinical support, and direct-to-patient fulfillment. The company's diversified business model, which spans both business-to-business (B2B) and business-to-consumer (B2C) channels, is proving to be a key driver of revenue growth and financial improvement. In FY2026, ETST reported revenue of $35.7 million, a notable increase from $33.1 million in FY2025 and a substantial leap from $11.95 million in FY2024. This growth trajectory underscores the effectiveness of the company's strategy to serve independent clinics while also selling customized medications directly to consumers.

The implications of this announcement are significant for investors and the healthcare industry alike. ETST's ability to generate positive operating cash flow while reducing total liabilities from $3.146 million to $1.928 million and increasing assets from $7.066 million to $8.969 million demonstrates a strengthening financial position. Moreover, the company has fully repaid its long-term debt, eliminating a major financial burden. This debt reduction, coupled with the expectation that operating cash flow will fund FY2027 needs without additional dilutive financing, highlights a disciplined approach to growth. By avoiding debt or shareholder dilution, ETST is preserving value for existing shareholders and signaling confidence in its internal cash generation capabilities.

ETST's business model is centered on the seamless integration of patient care, from consultation to fulfillment, through its subsidiaries RxCompoundStore, Mister Meds, and Peaks Curative. This synergy allows the company to address the growing demand for personalized healthcare solutions. The B2B component serves independent clinics, providing them with compounding pharmacy services and clinical support, while the B2C arm directly reaches consumers with customized medications. This dual approach not only diversifies revenue streams but also creates multiple touchpoints across the healthcare continuum, from physical to digital operations.

The company's focus on vertical integration is a strategic move in an industry where fragmentation often leads to inefficiencies. By controlling the entire process—from telemedicine consultations to the compounding of medications and final delivery—ETST can ensure quality, consistency, and cost-effectiveness. This integrated model also allows for better patient outcomes and satisfaction, as it streamlines what is typically a complex and disjointed experience for patients.

For investors, the financial results and strategic direction of ETST present a compelling case. The revenue growth from FY2024 to FY2026 indicates strong demand for its services, and the improvement in the balance sheet reflects prudent financial management. The company's ability to fund future growth through operating cash flow rather than external financing reduces risk and enhances long-term sustainability. As ETST continues to execute its strategy, it is well-positioned to capitalize on trends in telemedicine, personalized medicine, and direct-to-consumer healthcare.

To view the full article, visit https://nnw.fm/oJY5L. For more information about Earth Science Tech, please visit www.EarthScienceTech.com. The latest news and updates relating to ETST are available in the company's newsroom at https://nnw.fm/ETST.